Compare Credo Technology Group Holding Ltd (CRDO) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Credo Technology Group Holding Ltd vs Illumina, Inc. — how do they compare? Credo Technology Group Holding Ltd trades at $256.95 (market cap $46.19B), while Illumina, Inc. trades at $193.06 (market cap $29.12B). The key difference: Credo Technology Group Holding Ltd is the larger of the two by market cap, and Illumina, Inc. is trading nearer its 52-week high, Credo Technology Group Holding Ltd nearer its low. Which is the better fit depends on your goals.
| CRDO | ILMN | |
|---|---|---|
Market Cap | $46.19B | $29.12B |
Sector | Technology | Health |
52-Week High | $302.52 | $205.10 |
52-Week Low | $87.81 | $91.00 |
Enterprise Value | $44.77B | $30.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRDO trades at $249.89, up 8.45% today, with strong technical momentum above key support at $237. The stock shows exceptional fundamental growth with revenue surging from $437M in 2025 to $1.3B projected for 2026, while maintaining robust 35.37% net margins. Recent news highlights Credo's strategic positioning in AI infrastructure through contributions to the Open Compute Project and institutional accumulation.
Outlook remains positive given accelerating AI capex and strong analyst consensus (86.7% buy ratings) with $285.42 price target. Key risks include premium valuation (P/E 95.6), customer concentration, and execution challenges in scaling operations amid competitive AI infrastructure landscape.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Credo Technology Group Holding Ltd
Credo Technology provides high-speed connectivity solutions for AI-driven applications and hyperscale data centers. Its products enable faster, more energy-efficient data transmission for cloud and telecom infrastructure.
Read more on CRDO →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
